



2025

Taipei International Breast Cancer Symposium

台北國際乳癌研討會

Topic:

Cardio-Oncology at NCKUH: Breast Cancer and Cardiotoxicity — Progress and Future Directions

Abstract

Cancer therapy-related cardiac dysfunction (CTRCD) is a major challenge for oncologists and hematologists, as its occurrence often forces a choice between interrupting cancer therapy to address cardiac complications and risking cancer progression. With cancer survival improving through novel therapeutics, the burden of therapy-related cardiovascular complications is expected to rise, yet many uncertainties remain.

For over a decade, National Cheng Kung University Hospital (NCKUH) has advanced the cardio-oncology concept through close collaboration among cardiologists, oncologists, and hematologists to prevent, monitor, and manage cardiovascular complications during cancer therapy. This year, we reported a phase II clinical trial demonstrating the primary preventive effect of sacubitril/valsartan against cardiotoxicity in patients with early-stage breast cancer receiving adjuvant therapy. This finding not only supports a promising pharmacological option for prevention but also reflects the strength of our multidisciplinary teamwork, rigorous monitoring, timely treatment, and comprehensive follow-up.

Building on these results and experience, we remain committed to advancing cardiovascular care for patients with cancer and warmly invite colleagues to join us in this effort.